Why GlaxoSmithKline PLC Shrugged Off Alli's Recall

GlaxoSmithKline issued a voluntary recall for its OTC weight-loss pill Alli last week. Will this recall have a material impact on GlaxoSmithKline's business?

Mar 30, 2014 at 4:30PM

GlaxoSmithKline (NYSE:GSK) announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that were not the FDA-approved weight-loss product. Alli is an OTC version of Roche Holdings AG's prescription drug Xenical, containing about half as much as orlistat, the active ingredient, as Xenical. Both drugs are meant to be taken in conjunction with a healthy diet and exercise.

Despite the headline-grabbing nature of this news, GlaxoSmithKline's shares reacted almost indifferently, even ending the week in positive territory. That's saying something, especially in a week where the iShares Nasdaq Biotechnology Index (NASDAQ:IBB) fell 6.76%. So, why did GlaxoSmithKline's shares shrug off this bad news?

Alli -- a history of problems and disappointments
In 2011, GlaxoSmithKline announced that it was actively shopping Alli, along with other non-prescription brands, to potential buyers. This news was certainly disappointing for investors, because the drug was originally believed to have blockbuster potential when it was launched in 2007. Even so, Alli's sales peaked around $337 million in 2009, and had fallen sharply to $93 million by 2011. This major drop is thought to be the result of a 2009 Consumer Reports article stating that, a Freedom of Information Request filed with the FDA produced information that orlistat appeared to be linked to an increased risk of rectal bleeding, as well as kidney, liver, and thyroid problems. Following the report, the FDA revised the label for products containing orlistat to include new safety information about cases of severe liver injury. Alli's new label specifically contained a new warning about "rare reports of severe liver injury."

Complicating matters, Roche had manufacturing problems with orlistat in 2011 that greatly reduced the supply of Alli, and even kept the drug from being included in a deal with Omega Pharma for a host of GlaxoSmithKline's OTC health care brands in Europe. Since 2011, GlaxoSmithKline has stopped breaking out Alli's sales in their financial reports, showing how far the drug has fallen in the eyes of management. 

New drugs, new problems for Alli
Although Alli remains the only FDA-approved OTC weight-loss drug, it is undoubtedly facing competition from the new generation of prescription-based meds, namely Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq and VIVUS's (NASDAQ:VVUS) Qsymia. Moreover, Orexigen Therapeutics (NASDAQ:OREX) and Novo Nordisk could both have additional anti-obesity drugs on the market by the end of the year. Because the obesity market has proved to be a tough nut to crack for pharmaceuticals in general, this slate of new prescription drugs could make it even harder for medications like Alli/Xenica in terms of commercial performance, given their modest weight loss and problematic side effects. Indeed, Belviq thus far appears to be a relatively safe weight-loss option, whereas Qsymia can lay claim to superior performance in terms of weight-loss than all other commercially available pills. In sum, Alli's sales are probably going to continue to head lower, as more and more pharmaceutical options with superior weight-loss and safety profiles become available.

Foolish wrap-up
Recalls for consumer goods can have a dramatic affect on a company's share price due to the cost and loss of revenue involved. In this case, GlaxoSmithKline's shares barely moved on the news, in part, because Alli has become a minor player in their consumer health care commercial portfolio, and the future of the drug is uncertain due newer drugs coming on the market. Although Alli's sales haven't been reported recently, it's also important to remember that GlaxoSmithKline is a huge company and they could probably mothball Alli altogether without much impact on their bottom line. Specifically, the company booked a stately $8.83 billion in profits after taxes in 2013. So, you shouldn't expect much overhang from the recall of Alli going forward. 

Boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers